Pacira BioSciences stock (US6951271005): Activist investor DOMA nominates three board directors

DOMA Perpetual Capital Management, which owns 7.5% of Pacira BioSciences, has nominated three independent directors to the board, citing concerns over revenue growth and operational efficiency.

Pacira BioSciences faces a proxy contest as activist investor DOMA Perpetual Capital Management has nominated three independent board candidates, according to a definitive proxy statement filed on May 13, 2026. DOMA, which beneficially owns approximately 7.5% of Pacira's outstanding shares, is urging shareholders to vote for its slate of highly qualified independent directors at the upcoming annual meeting.

The nomination comes amid scrutiny of Pacira's financial performance. According to Investing.com as of May 13, 2026, Pacira's total revenues increased just 4% in 2025, while research and development spending rose 44% and selling, general and administrative expenses increased 25%. This divergence between modest revenue growth and accelerating costs has drawn activist attention to the company's capital allocation strategy.

As of: May 14, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Pacira BioSciences, Inc.
• Sector/industry: Specialty pharmaceuticals, non-opioid pain management
• Headquarters/country: United States
• Core markets: Non-opioid pain management, regenerative health solutions
• Key revenue drivers: Pain management products and regenerative health therapies
• Home exchange/listing venue: Nasdaq (PCRX)
• Trading currency: USD
• Market capitalization: Approximately $906.62 million

Pacira BioSciences: core business model

Pacira BioSciences is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. Founded in 2006 and headquartered in the United States, the company operates in a sector increasingly focused on alternatives to opioid-based therapies, addressing a significant public health concern. Pacira's portfolio includes products designed for acute and chronic pain management across multiple therapeutic areas.

Main revenue and product drivers for Pacira BioSciences

The company's revenue generation relies on its non-opioid pain management portfolio and regenerative health offerings. According to the activist investor's filing, Pacira generated revenues with a 4% year-over-year increase in 2025, indicating a maturing product base. The company's strategic focus on non-addictive alternatives positions it within a growing market segment as healthcare providers and patients seek safer pain management options. However, the significant increase in R&D spending suggests Pacira is investing heavily in pipeline development to drive future growth.

Activist pressure and governance concerns

DOMA Perpetual's nomination of three board directors reflects broader concerns about operational efficiency and strategic direction. According to PR Newswire as of May 13, 2026, DOMA issued a letter to shareholders urging them to vote for its slate on the white proxy card. The activist's position reflects a view that current board composition may not be adequately addressing cost structure and capital efficiency issues, particularly given the 25% increase in SG&A expenses in 2025 alongside modest revenue growth.

Relevance for US investors

Pacira BioSciences trades on Nasdaq under the ticker PCRX and represents exposure to the specialty pharmaceutical sector, which is a significant component of the US healthcare market. The company's focus on non-opioid pain management aligns with regulatory and market trends favoring alternatives to opioid therapies, a priority for US healthcare policy. The activist contest provides US retail investors with visibility into governance dynamics and strategic debates within a mid-cap pharmaceutical company.

Conclusion

Pacira BioSciences faces a pivotal moment as DOMA Perpetual's board nomination contest brings governance and strategic execution into focus. The divergence between modest revenue growth and rising operational costs has prompted activist intervention, signaling investor concerns about capital allocation and management effectiveness. The outcome of the proxy contest will likely influence the company's strategic direction and cost management approach going forward. For US investors, the situation underscores the importance of monitoring governance developments and operational metrics in specialty pharmaceutical companies.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.